Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “BCG VACCINATION”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed1955

BCG Vaccinations.

Explore the source record for details and available documents.

BCG Vaccine↗
PubMed1951

[BCG vaccine].

Explore the source record for details and available documents.

BCG Vaccine↗
PubMed1976

[Biologic effect of atypical mycobacteria against a background of BCG vaccination].

A study was made of the specific sensitivity to tuberculin in the animals vaccinated with BCG in case of their additional sensitization with various atypical mycobacteria. The mentioned experimental study appeared to be necessary for the purpose of a more proper treatment of the epidemiological date referred to the sensitivity of man to tuberculin and sensitins against the background of mass BCG vaccination. Preliminary BCG vaccination of the animals with their subsequent infection with atypical mycobacteria altered the allergic response to the antigens from the mycobacteria increasing the response reactions not only to tuberculin, but also to sensitins from mycobacteria of the I--III groups by Runyon's classification, closely connected in antigenic respect with mycobacteria tuberculosis. Skin reactions to sensitins from the saprophytic mycobacteria which had in their composition much less common antigens with mycobacteria tuberculosis, remained at the low level. Sensitization with atypical mycobacteria of animals preliminarily vaccinated with BCG failed to cause significant influence on the production of immunity to the subsequent virulent infection with tuberculosis.

Animals↗
PubMed1981

Post-vaccination tuberculin sensitivity for assessing BCG vaccination in areas with high prevalence of non-specific sensitivity.

The relationship of non-specific sensitivity to post-vaccination tuberculin sensitivity has been the subject of controversy. This relationship has an important bearing on the common practice of using post-vaccination tuberculin sensitivity for assessing BCG vaccination in areas with a high prevalence of non-specific sensitivity. If post-vaccination tuberculin sensitivity is found to be dependent on the amount of already existing, naturally acquired, non-specific sensitivity it could not be considered a reliable measure of the success of BCG vaccination. In a recent BCG trial in India a large number of persons were tested with PPD-S and PPD-B and also vaccinated with BCG vaccine or injected with placebo, by random allocation. Mutually exclusive random samples of the study population were retested with PPD-S at 2 1/2 months, 2 1/2 years and 4 years after vaccination. At each post-vaccination test the tuberculin sensitivity obtained among the placebo-injected controls provided a measure of the tuberculin sensitivity due to non-specific sensitivity that would have been present in the absence of BCG vaccination. The difference between the mean size of reactions to the post-vaccination test among the vaccinated and among the unvaccinated controls provided a measure of tuberculin sensitivity that was wholly due to BCG vaccination. Thus it was possible to separate and study the two components of post-vaccination tuberculin sensitivity. The results of the study indicate that post-vaccination tuberculin sensitivity can be used to assess BCG vaccination in areas with a high prevalence of non-specific sensitivity, provided the assessment is done in younger age groups and based on post-vaccination tuberculin sensitivity as measured at 2-3 months after vaccination and not later.

Adolescent↗
PubMedDate not supplied

BCG vaccine and post-BCG complications among infants in Gaza Strip, 1999.

The relationship between post-BCG complications and the practices of administration and/or use of certain batches of BCG vaccine was investigated. A questionnaire were given to nurses administering BCG vaccination. An abstraction sheet was used to analyse cases with BCG complications among infants (n = 552) and schoolchildren (n = 97). The rate of complications was 14.7/1000 among infants and 2.5/1000 among schoolchildren in 1997. The complications rate was 19.1/1000 at UNRWA and 8.3/1000 at governmental health services. It was found that a single batch of BCG 2611-11 combined with incorrect administering of the vaccine was responsible for this outbreak of complications. Therefore, the establishment of a surveillance system to monitor adverse events following immunization is needed.

Abscess↗
PubMed1977

Neonatal vaccination with 'universal strength' BCG vaccine.

'Universal strength' BCG vaccine was given to 219 neonates and 2 months later 159 infants were Mantoux-tested with 5 Tu PPD-S and their BCG scars measured. The results showed a satisfactory conversion rate of over 90%. Though 30% of the lesions discharged, this only lasted for a few days and the vaccine was well tolerated and acceptable for use in neonates.

BCG Vaccine↗
PubMed1967

Lysed BCG vaccines. 2. The effect of lysis on the immunogenicity and allergenicity of BCG vaccines.

The authors have attempted to prepare lysed BCG vaccines retaining the protective antigens of the BCG cell wall and yet eliciting in experimental animals limited sensitivity to the tuberculin substances, the advantage sought being to retain the usefulness of the tuberculin following vaccination as an indicator of superinfection.Experimental vaccines were prepared by growing and lysing BCG in both Dubos and Aldridge liquid media with glycine, lysosyme and lithium chloride; vaccines were also prepared by autolysis in Aldridge nitrogen-deficient, chemically defined medium.Glycine, lysozyme and lithium chloride significantly reduced both the protective and allergenic properties of the lysates. The best protection was afforded by BCG cells autolysed in Aldridge medium. Treatment of the BCG autolysates with lysozyme alone did not affect the protective capability of the vaccines and almost completely eliminated the allergenicity. It is suggested that these BCG lysates contain metabolically inactive cells, which do not multiply in vitro but may still provide sufficient antigen in vivo to ensure protection.

Animals↗